UY30051A1 - Derivados de pirimidina para el tratamiento del crecimiento celular anormal - Google Patents
Derivados de pirimidina para el tratamiento del crecimiento celular anormalInfo
- Publication number
- UY30051A1 UY30051A1 UY30051A UY30051A UY30051A1 UY 30051 A1 UY30051 A1 UY 30051A1 UY 30051 A UY30051 A UY 30051A UY 30051 A UY30051 A UY 30051A UY 30051 A1 UY30051 A1 UY 30051A1
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- cellular growth
- abnormal cellular
- pirimidine derivatives
- mammals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a un conpuesto de fórmula 1 o una sal farmacéuticamente aceptable del mismo, en la que AR es un grupo de fórmula y R1, R2, R13, A, K, Ml L1, L2, X, Y1, Y2, Q sal del mismo, en la que R1, R2, R13, A, K, L1, L2, W, X, Z, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p y q son como se handefinido en este documento. Dichos nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como cáncer, en mamíferos. Esta invención también se refiere a un procedimiento de uso de dichos compuestos en el tratamiento del crecimiento celular anormal en mamíferos, especilamente seres humanos, y a composiciones farmacéuticas que contienen dichos compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75270805P | 2005-12-21 | 2005-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30051A1 true UY30051A1 (es) | 2007-07-31 |
Family
ID=38038639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30051A UY30051A1 (es) | 2005-12-21 | 2006-12-21 | Derivados de pirimidina para el tratamiento del crecimiento celular anormal |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7820648B2 (es) |
| EP (1) | EP1966207A2 (es) |
| JP (1) | JP4332590B2 (es) |
| KR (1) | KR101060051B1 (es) |
| CN (1) | CN101346380B (es) |
| AP (1) | AP2008004488A0 (es) |
| AR (1) | AR058399A1 (es) |
| AU (1) | AU2006327871A1 (es) |
| BR (1) | BRPI0620324A2 (es) |
| CA (1) | CA2634646C (es) |
| CR (1) | CR10095A (es) |
| DO (1) | DOP2006000289A (es) |
| EA (1) | EA014551B1 (es) |
| EC (1) | ECSP088563A (es) |
| GT (1) | GT200600517A (es) |
| HN (1) | HN2006042221A (es) |
| IL (1) | IL191555A0 (es) |
| MA (1) | MA30075B1 (es) |
| ME (1) | MEP0908A (es) |
| NL (1) | NL2000375C2 (es) |
| NO (1) | NO20082338L (es) |
| PE (1) | PE20071138A1 (es) |
| RS (1) | RS20080272A (es) |
| SV (1) | SV2008002969A (es) |
| TN (1) | TNSN08270A1 (es) |
| TW (1) | TW200736258A (es) |
| UA (1) | UA89123C2 (es) |
| UY (1) | UY30051A1 (es) |
| WO (1) | WO2007072158A2 (es) |
| ZA (1) | ZA200804488B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| EP2041132A2 (en) * | 2006-07-06 | 2009-04-01 | Boehringer Ingelheim International GmbH | New compounds |
| ES2633318T3 (es) | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| EP2183225A1 (en) * | 2007-07-17 | 2010-05-12 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| JP2011515372A (ja) * | 2008-03-20 | 2011-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリミジン類の位置選択的製造法 |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| TWI513694B (zh) * | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
| RU2013147417A (ru) | 2011-03-24 | 2015-04-27 | Кемилиа Аб | Новые производные пиримидина |
| CA2858420A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract |
| JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−２，４−ジアミン誘導体 |
| CN103655577A (zh) * | 2012-09-20 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105130907B (zh) * | 2015-07-29 | 2018-10-16 | 沈阳药科大学 | 嘧啶类化合物及其用途 |
| JP6946412B2 (ja) | 2016-07-18 | 2021-10-06 | ヤンセン ファーマシューティカ エヌ．ベー． | タウｐｅｔ画像化リガンド |
| US20200038513A1 (en) * | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| US20240025887A1 (en) * | 2021-01-07 | 2024-01-25 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| NZ539823A (en) | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2004067516A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| CA2564199A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1751143A1 (en) * | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2006
- 2006-12-11 EP EP06831737A patent/EP1966207A2/en not_active Withdrawn
- 2006-12-11 UA UAA200807169A patent/UA89123C2/ru unknown
- 2006-12-11 CA CA2634646A patent/CA2634646C/en not_active Expired - Fee Related
- 2006-12-11 AP AP2008004488A patent/AP2008004488A0/xx unknown
- 2006-12-11 CN CN2006800487340A patent/CN101346380B/zh not_active Expired - Fee Related
- 2006-12-11 WO PCT/IB2006/003655 patent/WO2007072158A2/en active Application Filing
- 2006-12-11 ME MEP-09/08A patent/MEP0908A/xx unknown
- 2006-12-11 RS RSP-2008/0272A patent/RS20080272A/sr unknown
- 2006-12-11 BR BRPI0620324-8A patent/BRPI0620324A2/pt not_active IP Right Cessation
- 2006-12-11 EA EA200801287A patent/EA014551B1/ru not_active IP Right Cessation
- 2006-12-11 KR KR1020087017637A patent/KR101060051B1/ko not_active IP Right Cessation
- 2006-12-11 AU AU2006327871A patent/AU2006327871A1/en not_active Abandoned
- 2006-12-11 JP JP2008546669A patent/JP4332590B2/ja not_active Expired - Fee Related
- 2006-12-14 NL NL2000375A patent/NL2000375C2/nl not_active IP Right Cessation
- 2006-12-19 DO DO2006000289A patent/DOP2006000289A/es unknown
- 2006-12-19 GT GT200600517A patent/GT200600517A/es unknown
- 2006-12-20 HN HN2006042221A patent/HN2006042221A/es unknown
- 2006-12-20 AR ARP060105660A patent/AR058399A1/es not_active Application Discontinuation
- 2006-12-20 US US11/613,390 patent/US7820648B2/en not_active Expired - Fee Related
- 2006-12-20 TW TW095147907A patent/TW200736258A/zh unknown
- 2006-12-20 PE PE2006001661A patent/PE20071138A1/es not_active Application Discontinuation
- 2006-12-21 UY UY30051A patent/UY30051A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 IL IL191555A patent/IL191555A0/en unknown
- 2008-05-22 NO NO20082338A patent/NO20082338L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804488A patent/ZA200804488B/xx unknown
- 2008-06-19 EC EC2008008563A patent/ECSP088563A/es unknown
- 2008-06-20 TN TNP2008000270A patent/TNSN08270A1/fr unknown
- 2008-06-20 SV SV2008002969A patent/SV2008002969A/es not_active Application Discontinuation
- 2008-06-20 MA MA31059A patent/MA30075B1/fr unknown
- 2008-06-20 CR CR10095A patent/CR10095A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30051A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| HN2005000212A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| BRPI0607455A2 (pt) | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica | |
| HK1139658A1 (en) | Benzimidazole derivatives | |
| ECSP066406A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| AR053412A1 (es) | Compuestos inhibidores de la interaccion entre mdm2 y p53, un metodo de preparadcion, composicion farmaceutica y uso del compuesto para fabricar medicamentos | |
| TW200612949A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| CO6321259A2 (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| CR8749A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| ECSP078062A (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| CR10199A (es) | Derivados de benzimidazol | |
| EA201000882A1 (ru) | Соединение, его применение и фармацевтическая композиция, содержащая это соединение | |
| ATE425948T1 (de) | Substituierte hydroxyacetophenonderivative | |
| CU20080126A7 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| NI200500205A (es) | "derivados de pirimidina para el tratamiento del crecimiento celular anorma." | |
| UA93313C2 (en) | Benzimidazole derivatives | |
| UY28136A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| DOP2005000086A (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
| TH105256A (th) | อนุพันธ์ไพริมิดีนสำหรับการรักษาการเจริญเติบโตของเซล์ที่ผิดปกติ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160928 |